As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance

Blockbuster Potential In Late-Stage Pipeline

 
• By Andrew McConaghie
Vertex Mobile
Vertex's CF sales are set to reach $8.5bn this year, but investors are already looking ahead to opportunities in new therapy areas. • Source: Shutterstock

More from Business

More from Scrip